Gossamer Bio, Inc. operates as a biopharmaceutical company. The Company focuses on discovering, acquiring, and developing therapeutics in the disease areas of immunology, inflammation, and oncology.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Gossamer Bio news
11.05.2022
Gossamer Bio's GAAP loss for 3 months of 2022 was $57.785 million, up 0.2% from $57.641 million in the prior year.
Source: 
ir.gossamerbio.com
ir.gossamerbio.com
04.03.2022
Gossamer Bio's GAAP loss for 2021 was $234.004 million, down 3.8% from $243.36 million in the previous year.
Source: ir.gossamerbio.com
ir.gossamerbio.com
09.11.2021
Gossamer Bio's GAAP loss for 9M 2021 was $177.72 million, down 0.6% from $178.756 million in the prior year.
Source: ir.gossamerbio.com
ir.gossamerbio.com
10.08.2021
Gossamer Bio's GAAP loss for 6M 2021 was $117.473 million, down 2.9% from $120.944 million in the prior year.
Source: ir.gossamerbio.com
ir.gossamerbio.com
General information
| Company name | Gossamer Bio |
|---|---|
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 3013 SCIENCE PARK SAN DIEGO CA 92121 (858) 922-0718 |
| Mailing address | 3013 SCIENCE PARK SAN DIEGO CA 92121 |
| Website | www.gossamerbio.com |
| Information disclosure | www.sec.gov |
English (US) 